News

h2o Therapeutics has partnered with AmerisourceBergen to commercialize Parky, a prescription mobile app that monitors symptoms in people with Parkinson’s disease, such as tremors and involuntary muscle movements. The Parky app monitors a patients’ symptoms in real time using an Apple Watch, and shares the data…

NeuroOne Medical Technologies‘ Evo stereoelectroencephalography (sEEG) electrodes for measuring or stimulating brain activity in people with neurological diseases like Parkinson’s disease or epilepsy are now available commercially in the U.S. The electrodes were approved by the U.S. Food and Drug Administration (FDA) in October for less than…

People newly diagnosed with Parkinson’s disease were found to have significantly lower blood levels of the argonaute 2 (AGO2) protein relative to healthy adults, according to a recent biomarker study conducted by NeuroSense Therapeutics. In people with amyotrophic lateral sclerosis (ALS), the company’s PrimeC treatment candidate previously…

PharmaTher Holdings has applied to the U.S. Food and Drug Administration (FDA) asking that ketamine be given fast-track designation as a potential treatment for dyskinesia, or uncontrolled movements, that occur as a side effect of levodopa being used by people with Parkinson’s disease. The fast-track designation is designed…

A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…

Abbvie is funding a clinical trial called PROSPECT to assess how clinical outcomes and disease burden change over time for people with Parkinson’s disease whose symptoms are not adequately controlled with available treatments. Interim data from the trial, presented at this year’s American Academy of Neurology (AAN) annual…

An assay using skin biopsies, called the Syn-One Test, was able to detect the alpha-synuclein protein that characterizes Parkinson’s disease and like conditions in more than 90% of the patients enrolled in a clinical trial. “These results validate cutaneous [skin-based] alpha-synuclein as a reliable biomarker for Parkinson’s disease and…

Noninvasive low-intensity focused ultrasound (LIFU) temporarily opened the blood-brain barrier to allow molecules to enter the brains of Parkinson’s disease patients, a study reports. In nonhuman primates, LIFU safely enhanced the delivery of a gene therapy model using a harmless, modified virus directly to the striatum, a region affected…

The investigational combination therapy P2B001 was similar to Mirapex (pramipexole) at controlling symptoms of Parkinson’s disease in a clinical trial. But patients treated with P2B001 were less likely to experience sleepiness and fewer had orthostatic hypotension (a sudden drop in blood pressure on standing) as side effects. Lawrence Elmer,…

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast…